Search Results - "Gray, David L."

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia by Arnsten, Amy F.T, Girgis, Ragy R, Gray, David L, Mailman, Richard B

“…Abstract Schizophrenia is characterized by profound cognitive deficits that are not alleviated by currently available medications. Many of these cognitive…”
Get full text

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor by Gray, David L., Allen, John A., Mente, Scot, O’Connor, Rebecca E., DeMarco, George J., Efremov, Ivan, Tierney, Patrick, Volfson, Dmitri, Davoren, Jennifer, Guilmette, Edward, Salafia, Michelle, Kozak, Rouba, Ehlers, Michael D.

“…Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a therapeutic strategy for neurologic and psychiatric diseases due to the…”
Get full text

Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network by Sciabola, Simone, Goetz, Gilles H., Bai, Guoyun, Rogers, Bruce N., Gray, David L., Duplantier, Allen, Fonseca, Kari R., Vanase-Frawley, Michelle A., Kablaoui, Natasha M.

“…[Display omitted] Oxytocin (OT) is a peptide hormone agonist of the OT receptor (OTR) that plays an important role in social behaviors such as pair bonding,…”
Get full text

The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey by Moore, Tara L, Young, Damon A, Killiany, Ronald J, Fonseca, Kari R, Volfson, Dmitri, Gray, David L, Balice-Gordon, Rita, Kozak, Rouba

“…Aged-related declines in cognition, especially working memory and executive function, begin in middle-age and these abilities are known to be mediated by the…”
Get full text

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation by Kozak, Rouba, Kiss, Tamás, Dlugolenski, Keith, Johnson, David E., Gorczyca, Roxanne R., Kuszpit, Kyle, Harvey, Brian D., Stolyar, Polina, Sukoff Rizzo, Stacey J., Hoffmann, William E., Volfson, Dmitri, Hajós, Mihaly, Davoren, Jennifer E., Abbott, Amanda L., Williams, Graham V., Castner, Stacy A., Gray, David L.

“…Selective activation of dopamine D1 receptors remains a promising pro-cognitive therapeutic strategy awaiting robust clinical investigation. PF-6142 is a key…”
Get full text

Total Synthesis of Hamigerans and Analogues Thereof. Photochemical Generation and Diels−Alder Trapping of Hydroxy-o-quinodimethanes by Nicolaou, K. C, Gray, David L. F, Tae, Jinsung

“…A number of naturally occurring substances, including hamigerans, contain ring systems which are fused to an aromatic nucleus. A general and streamlined method…”
Get full text

Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease by Lewis, Mechelle M., Van Scoy, Lauren J., De Jesus, Sol, Hakun, Jonathan G., Eslinger, Paul J., Fernandez-Mendoza, Julio, Kong, Lan, Yang, Yang, Snyder, Bethany L., Loktionova, Natalia, Duvvuri, Sridhar, Gray, David L., Huang, Xuemei, Mailman, Richard B.

“…Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson’s disease (LsPD) patients whose daily life depends…”
Get full text

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated by Sohur, U. Shivraj, Gray, David L., Duvvuri, Sridhar, Zhang, Yao, Thayer, Kathleen, Feng, Gang

“…Introduction There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel,…”
Get full text

Total Synthesis of Hybocarpone and Analogues Thereof. A Facile Dimerization of Naphthazarins to Pentacyclic Systems by Nicolaou, K. C, Gray, David L. F

“…The total synthesis of the lichen-derived antitumor agent hybocarpone (1) and related compounds is described. The successful route to hybocarpone features a…”
Get full text

Dopaminergic D1 receptor stimulation affects effort and risk preferences by Soutschek, Alexander, Gvozdanovic, Geraldine, Kozak, Rouba, Duvvuri, Sridhar, de Martinis, Nicholas, Harel, Brian, Gray, David L, Fehr, Ernst, Jetter, Alexander, Tobler, Philippe N

“…AbstractBACKGROUNDActivation of D1 receptors has been related to successful goal-directed behavior, but it remains unclear whether D1 receptor activation…”
Get full text

Dopaminergic D 1 Receptor Stimulation Affects Effort and Risk Preferences by Soutschek, Alexander, Gvozdanovic, Geraldine, Kozak, Rouba, Duvvuri, Sridhar, de Martinis, Nicholas, Harel, Brian, Gray, David L, Fehr, Ernst, Jetter, Alexander, Tobler, Philippe N

“…Activation of D receptors has been related to successful goal-directed behavior, but it remains unclear whether D receptor activation causally tips the balance…”
Get full text

A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex by Wang, Min, Datta, Dibyadeep, Enwright, John, Galvin, Veronica, Yang, Sheng-Tao, Paspalas, Constantinos, Kozak, Rouba, Gray, David L., Lewis, David A., Arnsten, Amy F.T.

“…Decades of research have emphasized the importance of dopamine (DA) D1 receptor (D1R) mechanisms to dorsolateral prefrontal cortex (dlPFC) working memory…”
Get full text

Osteoblasts Express the Inflammatory Cytokine Interleukin-6 in a Murine Model of Staphylococcus aureus Osteomyelitis and Infected Human Bone Tissue by Marriott, Ian, Gray, David L., Tranguch, Susanne L., Fowler, Vance G., Stryjewski, Martin, Scott Levin, L., Hudson, Michael C., Bost, Kenneth L.

“…Staphylococcus aureus is the single most common cause of osteomyelitis in humans. Incidences of osteomyelitis caused by S. aureus have increased dramatically…”
Get full text

Osteoblasts produce monocyte chemoattractant protein-1 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue by Marriott, Ian, Gray, David L., Rati, Dana M., Fowler, Vance G., Stryjewski, Martin E., Levin, L. Scott, Hudson, Michael C., Bost, Kenneth L.

“…Incidences of osteomyelitis caused by Staphylococcus aureus have increased dramatically in recent years, in part, due to the appearance of community-acquired…”
Get full text

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists by Sasane, Rahul, Bartels, Amy, Field, Michelle, Sierra, Maria I, Duvvuri, Sridhar, Gray, David L, Pin, Sokhom S, Renger, John J, Stone, David J

“…Recently the α1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target for the mitochondrial deficits in Parkinson disease…”
Get full text

Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists by GRAY, David L, WENJIAN XU, CAMPBELL, Brian M, DOUNAY, Amy B, BARTA, Nancy, BOROSKI, Susan, DENNY, Lynne, EVANS, Lori, STRATMAN, Nancy, PROBERT, Al

“…Compounds that are both norepinephrine reuptake inhibitors (NRI) and 5-HT1(A) partial agonists may have the potential to treat neuropsychiatric disorders…”
Get full text

Derivatives of (3 S)- N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity by Fish, Paul V., Barta, Nancy S., Gray, David L.F., Ryckmans, Thomas, Stobie, Alan, Wakenhut, Florian, Whitlock, Gavin A.

“…Carboxamide 9e, carbamate 11b and sulfonamide 13a were identified as potent NRIs with excellent selectivity over SRI and DRI, good in vitro metabolic stability…”
Get full text

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia by Arce, Estibaliz, Balice-Gordon, Rita, Duvvuri, Sridhar, Naylor, Melissa, Xie, Zhiyong, Harel, Brian, Kozak, Rouba, Gray, David L, DeMartinis, Nicholas

“…Background: PF-06412562 is an orally bioavailable, selective dopamine D1/D5 receptor partial agonist with a non-catechol structure under evaluation for…”
Get full text

D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects by Young, Damon, Popiolek, Michael, Trapa, Patrick, Fonseca, Kari R, Brevard, Julie, Gray, David L, Kozak, Rouba

“…Parkinson’s disease is a progressive neurodegenerative disease characterized by striatal dopaminergic loss. L-DOPA treatment replaces lost dopamine and enables…”
Get full text

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity by Balice-Gordon, Rita, Honey, Garry D, Chatham, Christopher, Arce, Estibaliz, Duvvuri, Sridhar, Naylor, Melissa Graham, Liu, Wenlei, Xie, Zhiyong, DeMartinis, Nicholas, Harel, Brian T, Braley, Gabriel H, Kozak, Rouba, Park, Lovingly, Gray, David L

“…Dopamine D1 receptor signaling plays key roles in core domains of neural function, including cognition and reward processing; however, many questions remain…”
Get full text